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To assess the effect of nesiritide on the endothelial function of iliac arteries following endothelia 
trauma. Right iliac artery trauma was created with a balloon catheter. Ten rabbits were treated with 
a 4-week subcutaneous injection of nesiritide at a fixed daily dose of 0.1mg/kg. Ten rabbits received 
daily normal saline injection. Plasma endothelin 1 (ET-1), nitric oxide (NO), and Von Willebrand 
Factor (vWF) were measured before and after the therapies. Tissue proliferating cell nuclear antigen 
(PCNA) was measured after the treatment. After the treatment, in the therapeutic group, the area under 
internal elastic membrane and the residual lumen area were higher than in the normal saline group 
(P <0.05). The plasma levels of ET-1 (91.6±6.8 vs 114.9±6.3 ng/L, P =0.001), vWF (134.6±10.8% 
vs 188.8±10.4%, P =0.001) and the ratio of PCNA positive expression (11.7±4.2% vs 36.2±11.4%, P 
=0.005) in the therapeutic group was lower than in the normal saline group, while the plasma levels 
of NO was higher (89.7±9.3 vs 43.5±5.3 μmol/L, P =0.001). Nesiritide inhibited remodeling of rabbit 
iliac artery following endothelial trauma. The inhibition of vascular remodeling may be related to the 
alleviated endothelial dysfunction and reduced expression of tissue proliferating cell nuclear antigen.
Keywords: Plasma endothelin (ET-1). Nitric oxide (NO). von Willebrand Factor (vWF). Tissue 
proliferating cell nuclear antigen. Iliac artery.
INTRODUCTION
The B-type natriuretic peptide (BNP) is a vasoactive 
peptide. After more than two decades of active 
investigations, BNP has become a useful biomarker for the 
diagnosis of congestive heart failure and risk stratification 
of this prevalent and chronic condition (Egom, 2015; We 
et al. 2005a, 2005b, 2005c; Sun et al., 2007). BNP exerts 
protective effects against the post-myocardial infarction 
remodeling processes. In rats, BNP treatment inhibits 
extracellular matrix remodeling following acute myocardial 
infarction, and preserves ventricular function (Pan et al., 
2011; Plante et al. 2014). BNP plays an important role in 
modulating vascular endothelial function, and predicts 
the endothelial function in human subjects (Menon et al., 
2009; Pauriah et al., 2012). Nesiritide, a synthetic BNP, 
has been used to treat acute decompensated heart failure 
for more than a decade (Chen et al., 2013). Currently, there 
is a lack of understanding about the associations between 
nesiritide and vascular endothelial function. In human 
subjects, nesiritide treatment has been shown to suppress 
fibrosis and hypertrophy in the myocardium, and reduce 
end-diastolic volume a month after the treatment (Chen 
et al., 2009). In a porcine model of acute myocardial 
infarction, nesiritide infusion reduced the size of infarct 
and preserved coronary endothelial function (Lazar 
et al., 2009).
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Our previous studies in a rabbit model have 
found that nesiritide treatment inhibited vascular 
remodeling following arterial injuries, and the 
improved remodeling profile was due to reduced 
plasma aldosterone levels (Liu et al., 2010, 2012). 
However, it is unclear if nesiritide can protect injury-
induced endothelial dysfunction. Endothelin-1 (ET-1) 
is an endogenous vasoconstrictor that is involved in 
systemic and pulmonary hypertension. It also impacts 
on cardiac function and is associated with a higher 
mortality rate in patients with heart failure (Perez et al., 
2016). Nitric oxide (NO) is an endogenous vasodilator 
that regulates systemic and pulmonary circulation, as 
well as cardiovascular remodeling (Chen et al., 2014). 
von Willebrand Factor (vWF) is a molecule that is 
released from the vascular endothelium, leading to 
hypercoagulability and thrombosis. Balloon dilation 
of peripheral arteries were associated with an elevation 
in blood vWF (Yao, Wang, Kang, 2016). 
Although BNP has been shown to improve 
endothelial function in a variety of chronic cardiovascular 
conditions, the impact of nesiritide treatment on plasma 
ET-1, NO, and vWF following vascular injuries has not 
been reported. In this study, we investigated the changes 
in plasma ET-1, NO, vWF and neointimal proliferation 
following nesiritide therapy in a rabbit model that we 
have previously reported (Liu et al., 2010, 2012).
MATERIAL AND METHODS
Induction of arterial trauma
The Animal Ethics Committee of our hospital 
approved the present study, and the study protocols 
have followed the national guidelines. All steps 
have been taken to minimize the animals’ pain and 
suffering during and after the operations. A total of 
20 male rabbits were used for this study. The weight 
of the animals was 2.3 ± 0.2 kg (2.1-2.6 kg), with a 
median age of 5 months. Arterial trauma was induced 
with a balloon-catheter (Liu et al., 2010, 2012). First, 
under room temperature, ketamine (20mg/kg) was 
intravenously injected. Under ultrasound guidance, 
we inserted a Medtronic balloon catheter (Medtronic, 
MN, USA) to the common iliac artery where the 
catheter was inflated to a 5-atmosphere pressure (Liu 
et al., 2010, 2012) to create trauma to the arterial wall. 
Subsequently, we divided the animals into two groups, 
with 10 animals in each group. In one group (the 
therapeutic group), nesiritide (Shanghai GL Biochen, 
Shanghai, China) was injected subcutaneously at a 
daily dose of 0.1 mg/kg for a total of 4 weeks. This 
dosage was based on our previous studies in the same 
animal model, and proved to be the most effective (Liu 
et al., 2010, 2012). In the control group, normal saline 
was injected subcutaneously for the same period as 
the therapeutic group.
Histological studies
Haematoxylin and Eosin (HE) staining was used 
to study the vascular tissues which were collected at the 
end of the experiments (Liu et al., 2010, 2012). Tissue 
sections were studied by an imaging system (model 
ES2050, WD Technologies, Beijing, China). In each 
sections of the iliac artery, the area under internal elastic 
membrane (AUIEM), intimal area and residual lumen 
area were measured by two independent pathologists. 
The ratio of stenosis of the iliac artery was calculated 
by (AUIEM-residual lumen area)/AUIEM.
Plasma endothelin-1 (ET-1), nitric oxide (NO),  
and von Willebran factor (vWF)
Plasma ET-1 and vWF were measured by enzyme-
linked immunosorbent assay (ELISA). Plasma NO was 
measured by a nitrate reduction method. A commercial 
ELISA kit (Bogoo Biological Engineering Co, Shanghai, 
China) was used for ET-1 and vWF measurement. The 
NO kit was provided by Jiancheng Institute of Biological 
Engineering (Nanjing, China). 
Immunohistochemistry for proliferating 
cell nuclear antigen (PCNA) 
A commercially available immunohistochemistry 
kit (Boster Biological Engineering, Wuhan, China) 
was used to determine PCNA in the vascular tissues. 
Vascular tissue sections were stained with mouse anti-
rabbit PCNA antibodies, and the slides were examined 
by optical microscope (×200). All cells in each of 
the 10 visual fields, including the cells with positive 
PCNA expression (brown stains) were counted and 
recorded manually. The ratio between PCNA positive 
cells and total cells was defined as the positive PCNA 
expression rate. Two readers performed the cell counts 
and the means of the two sets of readings were used as 
the results. 
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Statistical analysis
SPSS software (Version 13, IBM SPSS Statistics, 
NY, USA) was used in thestatistical analysis of data. 
Data expression was in the form of means ± standard 
deviation. Numerical data and categorical data were 
analyzed by an independent student’s t and Fisher’s 
exact test, respectively. Statistical significance was 
determined at p≤0.05.
RESULTS
Effect of nesiritide on the structure 
of the iliac arteries
The two remodeling measures (AUIEM and 
residual lumen areas) in the control animals were lower 
than the therapeutic group animals (P =0.025 and P 
=0.001, respectively, Table I), whereas the stenosis ratio 
in the study group was higher (P =0.001, Table I). 
TABLE I - Comparison of remodeling indices between 






AUIEM (μm²) 493.7±139.3 643.2±134.1 0.025




Stenosis ratio (%) 37.1±9.2 18.54±7.8 0.001
AUIEM: area under internal elastic membrane.
PCNA expression in the iliac arteries
No positive PCNA expression was observed in 
the tissues of the normal iliac arterial tissues (Figure 
1A). Traces of PCNA expression were found in the 
vascular structures of the animals from the therapeutic 
group (Figure 1B). However, strong PCNA expression 
were present in the endothelium, smooth muscles and 
interstitial cells of the iliac arteries of the control group 
rabbits (Figure 1C).
FIGURE 1 - Immunohistochemical PCNA staining (×200). 
Cells stained with brownish color were considered positive. 
(a) shows tissues from the non-injured left iliac arteries 
(n=10) from nesiritide group. No PCNA expression was 
found (arrow). (b) tissues from the injured right iliac artery 
tissue from the nesiritide group (n=10). Scattered PCNA 
expression displayed as yellow brown granules (arrow). 
The positive staining rate was 11.7±4.2%. (c) tissues 
from the injured right iliac artery from the control group 
(n=10) with dense PCNA expression (arrows). The positive 
staining rate was 36.0±11.2% (P <0.01 compared with 
nesiritide group).
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Plasma levels of ET-1, NO and vWF
Baseline levels of ET-1, NO and vWF were obtained 
before the treatment, with no difference observed 
between the therapeutic and control group rabbits (Table 
II, P >0.05). In all rabbits, the levels of plasma ET-1 and 
vWF were increased, while NO levels were decreased 
at the end of the 28-day treatment. However, the post-
treatment levels of plasma ET-1 and vWF levels in the 
therapeutic group rabbits were lower than the control 
group rabbits, while the NO levels were significantly 
higher (Table II, P =0.001).
DISCUSSION
In this experimental work, we found that treatment 
with nesiritide for four weeks reduced the degree of 
vascular remodeling in the iliac arteries of the rabbits. 
We also found that there was a subdued increase in ET-1 
and vWF in the systemic circulation after nesiritide 
therapies, and a greater elevation in the circulating 
NO levels. These results suggest that the alleviation in 
endothelial dysfunction and the improved biosynthesis 
of NO may be the contributing factors for the therapeutic 
effect of nesiritide against vascular trauma. 
Vascular remodeling is characterized by disordered 
proliferation and migration of vascular smooth muscle 
cells, leading to vascular stenosis and tissue ischemia. 
Vascular remodeling is implicated in several cardiovascular 
diseases, such as pulmonary hypertension, ventricular 
hypertrophy, heart failure and myocardial infarction. 
Endothelium plays a critical role in regulating circulatory 
and vital organ functions, as well as vascular remodeling 
after vascular injuries or insults. Endothelial injuries and 
subsequent dysfunction form the pathological basis of 
several cardiovascular disorders, such as coronary artery 
and cerebrovascular disease, which may result in organ 
failure (Lerman et al., 1991, 1995; Manoury, Montiel, 
Balligand, 2012; Meyer et al., 2006). Under certain 
stimulatory conditions, ET-1, NO and vWF are released 
from the vascular endothelium or vascular walls to exert 
their regulatory effects. Therefore, the plasma levels of ET-
1, NO and vWF can be used as the circulating biomarkers 
for endothelial function. Elevation of ET-1 and vWF, 
and decline in NO may reflect endothelial dysfunction 
(Lerman et al., 1991, 1995; Manoury, Montiel, Balligand, 
2012; Meyer et al., 2006).
The main physiological function of ET-1 is to 
stimulate the growth of vascular smooth muscle cells 
and cause vasoconstriction (Lerman et al., 1991, 1995). 
The effects of NO are much more complex. They 
include vasodilation, inhibition of platelet aggregation, 
proliferation and migration of smooth muscle cells 
(Manoury B). NO also prevents cardiovascular trauma 
or insult, and alleviates vascular remodeling. NO 
also helps to protect endothelium against physical or 
chemical injuries (Manoury, Montiel, Balligand, 2012). 
The physiological or pharmacological roles of vWF are 
not well understood. It seems vWF helps to clearing 
out circulating coagulation factor VIII, and is therefore 
involved in the coagulation processes, particularly in 
the presence of trauma to the vascular endothelium 
(Lenting, Christophe, Denis, 2015; Mannucci, 1998).
A number of experimental and clinical studies have 
demonstrated that BNP can suppress vascular remodeling 
and improve hemodynamics by improving endothelial 
function. In cultured pulmonary arterial smooth muscle 
cells, BNP inhibited proliferation and migration of the 
TABLE II - Comparison of plasma ET-1, NO and vWF levels between nesiritide and control group
Control (n=10) Nesiritide (n=10)
P (Post-treatment)
Baseline Post-treatment Baseline Post-treatment
NO (μmol/L) 95.56±5.85 43.45±5.331) 96.51±6.48 89.66±9.251) 0.001
ET-1 (ng/L) 75.71±5.63 114.93±6.261) 74.98±5.96 91.59±6.761) 0.001
vWF (%) 102.94±11.42 188.84±10.361) 104.70±10.56 134.59±10.811) 0.001
1) P <0.01 compared with baseline value of the same group. NO: nitric oxide; ET-1: endothelium 1; vWF: Von Willebrand 
factor
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cells induced by angiotensin II (Hsu et al., 2014). BNP 
also inhibits angiotensin II or ET-1 induced ventricular 
hypertrophy (Volpe, 2014). Treatment with BNP for 
four weeks was associated with a reduced endothelial 
expression of vascular endothelial growth factor, and 
reduced stenosis after vascular injuries (Liu et al., 
2010). Furthermore, intravenous infusion of a BNP, 
such as nesiritide, decreased pulmonary capillary wedge 
pressure, which is beneficial to the treatment of acute 
decompensated heart failure (Volpe, 2014).
In the present study, we found that nesiritide 
therapies diminished the degree of the remodeling of 
the iliac artery following physical trauma to the blood 
vessels. Furthermore, nesiritide therapies was associated 
with a greater reduction in circulatory ET-1 and vWF 
levels, and a greater elevation in the NO levels. These 
results indicate that nesiritide improved the endothelial 
function after the vascular trauma, which may have 
contributed to the attenuated vascular remodeling in the 
injured iliac arteries.
Tissue PCNA expression is a result of cell 
proliferation. Therefore, the levels of tissue PCNA have 
been used as a marker for cell proliferation (Suzuki et 
al., 2000). Other investigators have found that, in a rat 
model of vascular trauma, overexpression of PCNA 
was present in thickened neointima of the damaged 
blood vessels (Wei et al., 1997). In the present study on 
a rabbit model, no PCNA expression was found in the 
normal iliac arteries. However, PCNA expression was 
identified in the traumatized iliac arteries, with a higher 
PCNA expression identified in the control group rabbits. 
These results suggest that nesiritide may have inhibited 
neointimal proliferation and vascular remodeling by 
suppressing vascular smooth muscle proliferation.
It remains unclear as to how nesiritide treatment 
reduced the plasma levels of ET-1 and vWF, and 
increased NO levels in our rabbit model of traumatic 
iliac artery injuries. Several animal and human studies 
have confirmed that natriuretic peptides stimulate NO 
production through the natriuretic peptide clearance 
receptor (NPR-C) (Houben et al., 2005). Stimulation of 
this NPR-C receptor decreased cAMP levels by adenylyl 
cyclase inhibition through an inhibitory guanine 
nucleotide-regulating protein (Houben et al., 2005). 
However, there is limited information about the cellular 
or molecular mechanisms by which brain natriuretic 
peptides or nesiritide influenced the endothelial 
expression of ET-1 or vWF. Therefore, further studies in 
this area are warranted. 
CONCLUSIONS
In this rabbit model, nesiritide improved endothelial 
function and inhibited neointima proliferation. The 
improved vascular remodeling following nesiritide 
treatment are associated with an elevated plasma levels 
of NO, and reduced levels of ET-1 and vWF, and reduced 
expression of PCNA in the vascular tissues. These novel 
results may have several potential clinical implications. 
Prophylactic treatment with nesiritide may reduce 
neointima proliferation or endothelial dysfunction 
following percutaneous coronary intervention (PCI), and 
diminish post-PCI coronary restenosis. Nesiritide may 
also be used to prevent vascular trauma from chronic 
insults, such as diabetes mellitus or hypertension, 
preventing ischemic injuries to vital organs such as 
kidneys or the heart. However, these potential clinical 
benefits require further investigations. 
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